ARGX - Company ID 0001697862
ARGENX SE trades as ARGX and has a market capitalization of $56.28 B, making it the #296 largest US-listed company by market value. This page tracks ARGENX SE through 272 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
| Filing | Type | Filed |
|---|---|---|
| 6-K | - | 2026-05-11 |
| 6-K | - | 2026-05-07 |
| 6-K | - | 2026-05-06 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| 6-K | - | 2026-04-20 |
| 6-K | - | 2026-03-20 |
| 20-F | - | 2026-03-19 |
| 6-K | - | 2026-03-19 |
Financial income for the three months ended March 31, 2026, was $44 million compared to $37 million for the same period in 2025. Income tax ...
$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth.
Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth ...
The largest companies sharing ARGENX SE's SEC industry classification (biological products, (no diagnostic substances)).
ARGENX SE (ARGX) has a market capitalization of $56.28 B as of 2026-07-09, ranking #296 among US-listed companies.